Extended Spectrum Beta-lactamases - Treatment, Carriage, Environmental Dissemination And Population Epidemiology
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 760
- 主要终点
- Treatment Failure
研究概览
简要总结
This project aims at investigating the duration of human fecal carriage of bacteria harboring plasmid-borne resistance genes expressing Extended Spectrum beta-lactamases (ESBL), risk factors for infections with such bacteria and persistence, mobility and spread of ESBL in the environment and within households. It also aims to compare different methods of detecting ESBL carriage and treat patients with urinary tract infection caused by these bacteria.
研究设计
- 研究类型
- Observational
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients >=18 of age with a urine culture yielding E. coli or K. pneumoniae >10.000 colony forming units/mL.
排除标准
- •Patients who have lived in Norway for <1 year
- •Patients who are unable to answer a questionaire
- •Patients who have been infected with an ESBL producing bacteria before
- •Patients who have been admitted to a hospital or a long term care facility for >24 hours during the past 31 days.
结局指标
主要结局
Treatment Failure
时间窗: 14 days after initiation of treatment
Patients included in the study with urinary tract infection (UTI) and treated as part of normal routine were followed for 14 days and further prescriptions of antimicrobials normally used for treatment of UTI will be considered treatment failures. Only participants that received pivmecillinam are reported here. In the paper published in PlosOne "High Rate of Per Oral Mecillinam Treatment Failure in Community-Acquired Urinary Tract Infections Caused by ESBL-Producing Escherichia coli" the mecillinam treatment group were compared with the group that did not receive mecillinam.
次要结局
- Subjective Outcome(14 days)